Section Arrow
NXTC.NASDAQ
- NextCure Inc
Quotes are at least 15-min delayed:2026/01/08 07:44 EST
Pre Market
Last
 14
+0.02 (+0.14%)
Bid
11
Ask
14.28
High 14 
Low 14 
Volume
Regular Hours (Closed)
Last
 13.98
+0.99 (+7.62%)
Day High 
13.98 
Prev. Close
12.99 
1-M High
14.645 
Volume 
51.97K 
Bid
11
Ask
14.28
Day Low
13.0975 
Open
13.17 
1-M Low
10.38 
Market Cap 
45.54M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.11 
20-SMA 12.15 
50-SMA 11.45 
52-W High 15.7399 
52-W Low 2.688 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-23.81/-3.47
Enterprise Value
50.69M
Balance Sheet
Book Value Per Share
6.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
Pre Market 0.128 +0.0024 +1.91%
ERASErasca5.17+1.54+42.42%-- 
Pre Market 4.55 -0.62 -11.99%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
Pre Market 4.81 -0.05 -1.03%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
Pre Market 13.78 +0.05 +0.36%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
Pre Market 23.35 +0.07 +0.30%
Industry overview quotes are at least 15 minutes delayed
Business Description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.